Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Statistical Decision Properties of Imprecise Trials Assessing COVID-19 Drugs

View ORCID ProfileCharles F. Manski, View ORCID ProfileAleksey Tetenov
doi: https://doi.org/10.1101/2020.05.26.20114009
Charles F. Manski
1Department of Economics and Institute for Policy Research, Northwestern University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Charles F. Manski
  • For correspondence: cfmanski@northwestern.edu
Aleksey Tetenov
2Geneva School of Economics and Management, University of Geneva
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Aleksey Tetenov
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

As the COVID-19 pandemic progresses, researchers are reporting findings of randomized trials comparing standard care with care augmented by experimental drugs. The trials have small sample sizes, so estimates of treatment effects are imprecise. Seeing imprecision, clinicians reading research articles may find it difficult to decide when to treat patients with experimental drugs. Whatever decision criterion one uses, there is always some probability that random variation in trial outcomes will lead to prescribing sub-optimal treatments. A conventional practice when comparing standard care and an innovation is to choose the innovation only if the estimated treatment effect is positive and statistically significant. This practice defers to standard care as the status quo. To evaluate decision criteria, we use the concept of near optimality, which jointly considers the probability and magnitude of decision errors. An appealing decision criterion from this perspective is the empirical success rule, which chooses the treatment with the highest observed average patient outcome in the trial. Considering the design of recent and ongoing COVID-19 trials, we show that the empirical success rule yields treatment results that are much closer to optimal than those generated by prevailing decision criteria based on hypothesis tests.

We have benefitted from the comments of Michael Gmeiner, Valentyn Litvin, Francesca Molinari, and John Mullahy. Tetenov has received funding from the Swiss National Science Foundation through grant number 100018-192580.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Tetenov has received funding from the Swiss National Science Foundation through grant number 100018_192580.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study did not perform original human-subjects research and, hence, did not require IRB approval.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The MATLAB code used to perform the computations is available from Aleksey Tetenov at https://tetenov.com/near_optimality.zip

https://tetenov.com/near_optimality.zip

https://tetenov.com/near_optimality_TableS1.csv

https://tetenov.com/near_optimality_TableS2.csv

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted June 15, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Statistical Decision Properties of Imprecise Trials Assessing COVID-19 Drugs
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Statistical Decision Properties of Imprecise Trials Assessing COVID-19 Drugs
Charles F. Manski, Aleksey Tetenov
medRxiv 2020.05.26.20114009; doi: https://doi.org/10.1101/2020.05.26.20114009
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Statistical Decision Properties of Imprecise Trials Assessing COVID-19 Drugs
Charles F. Manski, Aleksey Tetenov
medRxiv 2020.05.26.20114009; doi: https://doi.org/10.1101/2020.05.26.20114009

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (76)
  • Allergy and Immunology (202)
  • Anesthesia (55)
  • Cardiovascular Medicine (495)
  • Dentistry and Oral Medicine (91)
  • Dermatology (57)
  • Emergency Medicine (170)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (217)
  • Epidemiology (5746)
  • Forensic Medicine (3)
  • Gastroenterology (221)
  • Genetic and Genomic Medicine (883)
  • Geriatric Medicine (89)
  • Health Economics (233)
  • Health Informatics (776)
  • Health Policy (399)
  • Health Systems and Quality Improvement (256)
  • Hematology (105)
  • HIV/AIDS (187)
  • Infectious Diseases (except HIV/AIDS) (6580)
  • Intensive Care and Critical Care Medicine (397)
  • Medical Education (119)
  • Medical Ethics (28)
  • Nephrology (94)
  • Neurology (857)
  • Nursing (45)
  • Nutrition (143)
  • Obstetrics and Gynecology (166)
  • Occupational and Environmental Health (265)
  • Oncology (520)
  • Ophthalmology (168)
  • Orthopedics (44)
  • Otolaryngology (107)
  • Pain Medicine (48)
  • Palliative Medicine (22)
  • Pathology (150)
  • Pediatrics (257)
  • Pharmacology and Therapeutics (147)
  • Primary Care Research (116)
  • Psychiatry and Clinical Psychology (990)
  • Public and Global Health (2264)
  • Radiology and Imaging (380)
  • Rehabilitation Medicine and Physical Therapy (175)
  • Respiratory Medicine (314)
  • Rheumatology (110)
  • Sexual and Reproductive Health (83)
  • Sports Medicine (83)
  • Surgery (118)
  • Toxicology (25)
  • Transplantation (34)
  • Urology (42)